Paxmedica updated company presentation highlighting innovations in autism spectrum disorder treatments

Tarrytown, new york, march 13, 2024 (globe newswire) -- via ibn – paxmedica, inc. (nasdaq:pxmd), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. this comprehensive overview showcases paxmedica's strategic direction, recent advancements in asd therapeutics, and its commitment to addressing unmet needs within the asd community.
PXMD Ratings Summary
PXMD Quant Ranking